US Diabetes Devices Market Size
| Study Period | 2019- 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 25.16 Billion |
| Market Size (2029) | USD 34.10 Billion |
| CAGR (2024 - 2029) | 6.27 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
US Diabetes Devices Market Analysis
The United States Diabetes Devices Market size is estimated at USD 25.16 billion in 2024, and is expected to reach USD 34.10 billion by 2029, growing at a CAGR of 6.27% during the forecast period (2024-2029).
Diabetes is associated with many health complications. Comparing the population with and without diabetes, those with diabetes have a 300% increased risk of being hospitalized and, thus, incur more healthcare expenses compared to non-diabetic people. People with diabetes face a higher chance of experiencing serious complications from COVID-19. Doctors and the government are asking diabetes patients to check their glucose levels continuously. In general, people with diabetes are more likely to experience severe symptoms and complications when infected with a virus.
According to the AACE (American Association of Clinical Endocrinologists), recent studies have shown that of those hospitalized for severe disease, 22.2-26.9% reported living with diabetes. Diabetes and high glucose levels are associated with increased complications, respiratory failure, and mortality in hospitalized patients with coronavirus.
As of the most recent update in January 2022, diabetes remains a prominent health issue in the United States, impacting a considerable number of individuals. Approximately 34.2 million people, which accounts for 10.5% of the population, are living with diabetes. This figure encompasses both diagnosed and undiagnosed cases.
The majority of diabetes cases in the United States are classified as type 2 diabetes, making up around 90-95% of all diagnosed cases. Type 2 diabetes is closely associated with lifestyle factors such as obesity, physical inactivity, and poor dietary habits.
Although less prevalent, type 1 diabetes still affects a significant number of individuals, particularly children and young adults. It is estimated that approximately 1.6 million Americans have type 1 diabetes.
Thus due to increasing diabetes population in united states is driving the market in projected time frame.
US Diabetes Devices Market Trends
Growing Diabetes and Obesity Population in the United States
In the United States, the prevalence of diabetes has increased dramatically during the last two decades, a fact driven by the increased prevalence of obesity and lifestyle changes. Diabetes ranks among the fastest-growing chronic diseases in the United States. About 1.75 million US citizens are diagnosed with diabetes every year. The country also has the highest obesity population, which is a prominent cause of type-2 diabetes.
In the United States, several innovations by startups, like Glooko, OneDrop, Verily, Vacate, Insulet, Noom, Bigfoot Biomedical, Virta Health, Diabeloop, and Orgenesis, have launched in the market. The market for diabetes care devices is expected to experience steady growth in the coming years due to the greater prevalence of obesity due to less physical activity, unhealthy food habits, and other lifestyle factors. The growing awareness among people regarding advanced diabetes devices is improving their adaptability to diabetes devices.
Leading manufacturers are focusing on technological innovations and the development of advanced products to gain a substantial share of the market. There has been a significant rise in insulin delivery system technology, ranging from insulin injections to insulin pumps. Technological innovations and advancements offer many conveniences for measuring blood glucose levels.
Therefore, owing to the increasing prevalence of diabetes, the studied market is anticipated to witness growth over the analysis period.
Continuous Glucose Monitoring Segment is Expected to Witness Highest Growth Rate Over the Forecast Period
The continuous glucose monitoring segment recorded more than USD 2 billion in revenue in the current year, which is expected to further increase with a CAGR of more than 9% during the forecast period.
Continuous glucose monitoring sensors use glucose oxidase to detect blood sugar levels. Glucose oxidase converts glucose to hydrogen peroxidase, which reacts with the platinum inside the sensor, producing an electrical signal to be communicated to the transmitter. Sensors are the most important part of continuous glucose monitoring devices. Technological advancements to improve the accuracy of the sensors are expected to drive segment growth during the forecast period.
The frequency of monitoring glucose levels depends on the type of diabetes, which varies from patient to patient. Type-1 diabetic patients need to check their blood glucose levels at regular intervals to monitor their blood glucose levels and adjust their insulin dosing accordingly. The current CGM devices show a detailed representation of blood glucose patterns and tendencies compared to a routine check of glucose levels at set intervals. Furthermore, the current continuous glucose monitoring devices can either retrospectively display the trends in the levels of blood glucose by downloading the data or give a real-time picture of glucose levels through receiver displays.
The use of CGM by type-1 diabetic patients is very low as compared to type-2 diabetic patients. However, type-1 diabetic patients spend nearly twice as much on these devices as type-2 diabetics do. The newest CGM models, the Abbott Freestyle Libre and the Dexcom G6, overcame many technical barriers. However, people with type-2 diabetes have not used CGM as widely as they might due to their high costs and uncertainties regarding their necessity and efficacy.
Moreover, to lower the cost burden of diabetic patients in the United States, Abbott introduced a new, lower-priced category with Libre, at around USD 75 to USD 150 each month (2 sensors that last 14 days each). Continuous glucose monitoring devices are becoming cheaper with the advent of new technologies like cell phone integration, which is likely to drive segment growth during the forecast period.
US Diabetes Devices Industry Overview
The United States diabetes care devices market is semi-consolidated, with few significant and generic players. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market. There have been constant innovations driven by manufacturers such as Abbott and Medtronic, while also adhering to organic growth strategies, which is evident from the R&D spending of these companies.
US Diabetes Devices Market Leaders
-
Abbott
-
Dexcom
-
Becton Dickinson
-
Medtronic
-
F. Hoffmann-La Roche AG
*Disclaimer: Major Players sorted in no particular order
US Diabetes Devices Market News
- August 2023: The US Food and Drug Administration (FDA) has granted clearance for Roche's Accu-Chek Solo micropump system, a tubing-free "patch" pump for people with diabetes who use insulin.
- March 2022: Dexcom released G7 first in the U.K. and was expected to expand the launch across Europe throughout 2022. Meanwhile, the CGM system currently is under review by the Food and Drug Administration for an eventual U.S. release.
US Diabetes Devices Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Monitoring Devices
- 5.1.1 Self-monitoring Blood Glucose
- 5.1.1.1 Glucometer Devices
- 5.1.1.2 Blood Glucose Test Strips
- 5.1.1.3 Lancets
- 5.1.2 Continuous Glucose Monitoring
- 5.1.2.1 Sensors
- 5.1.2.2 Durables
-
5.2 Management Devices
- 5.2.1 Insulin Pump
- 5.2.1.1 Insulin Pump Device
- 5.2.1.2 Insulin Pump Reservoir
- 5.2.1.3 Infusion Set
- 5.2.2 Insulin Syringes
- 5.2.3 Cartridges in Reusable pens
- 5.2.4 Insulin Disposable Pens
- 5.2.5 Jet Injectors
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 COMPANY PROFILES
- 7.1.1 Becton and Dickenson
- 7.1.2 Medtronic
- 7.1.3 F. Hoffmann-La Roche AG
- 7.1.4 Insulet Corporation
- 7.1.5 Abbott
- 7.1.6 Dexcom
- 7.1.7 Tandem
- 7.1.8 Johnson & Johnson
- 7.1.9 Ypsomed Holding
- 7.1.10 Novo Nordisk
- 7.1.11 Sanofi
- 7.1.12 Eli Lilly and Company
- *List Not Exhaustive
-
7.2 COMPANY SHARE ANALYSIS
- 7.2.1 Self-monitoring Blood Glucose Devices
- 7.2.1.1 Abbott
- 7.2.1.2 F. Hoffmann-La Roche AG
- 7.2.1.3 LifeScan
- 7.2.1.4 Other Self-monitoring Blood Glucose Devices
- 7.2.2 Continuous Glucose Monitoring Devices
- 7.2.2.1 Dexcom
- 7.2.2.2 Medtronic
- 7.2.2.3 Abbott
- 7.2.2.4 Other Continuous Glucose Monitoring Devices
- 7.2.3 Insulin Devices
- 7.2.3.1 Omnipod
- 7.2.3.2 Novo Nordisk
- 7.2.3.3 Johnson & Johnson
- 7.2.3.4 Other Insulin Devices
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityUS Diabetes Devices Industry Segmentation
Patients with diabetes can monitor and control their blood glucose levels with the aid of diabetes devices. Diabetes patients' health can be dramatically improved by using diabetes devices. The United States diabetes device market is segmented into management devices and monitoring devices. The report offers the value (in USD) and volume (in units) for the above segments.
| Monitoring Devices | Self-monitoring Blood Glucose | Glucometer Devices |
| Blood Glucose Test Strips | ||
| Lancets | ||
| Monitoring Devices | Continuous Glucose Monitoring | Sensors |
| Durables | ||
| Management Devices | Insulin Pump | Insulin Pump Device |
| Insulin Pump Reservoir | ||
| Infusion Set | ||
| Management Devices | Insulin Syringes | |
| Cartridges in Reusable pens | ||
| Insulin Disposable Pens | ||
| Jet Injectors |
US Diabetes Devices Market Research FAQs
How big is the United States Diabetes Devices Market?
The United States Diabetes Devices Market size is expected to reach USD 25.16 billion in 2024 and grow at a CAGR of 6.27% to reach USD 34.10 billion by 2029.
What is the current United States Diabetes Devices Market size?
In 2024, the United States Diabetes Devices Market size is expected to reach USD 25.16 billion.
Who are the key players in United States Diabetes Devices Market?
Abbott, Dexcom, Becton Dickinson, Medtronic and F. Hoffmann-La Roche AG are the major companies operating in the United States Diabetes Devices Market.
What years does this United States Diabetes Devices Market cover, and what was the market size in 2023?
In 2023, the United States Diabetes Devices Market size was estimated at USD 23.58 billion. The report covers the United States Diabetes Devices Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the United States Diabetes Devices Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
US Diabetes Devices Industry Report
Statistics for the 2024 US Diabetes Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. US Diabetes Devices analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
